Doctors said that not treating the patient at the right time could have led to complications like meningitis of the brain, nasal bleeding, and loss of vision.

Mumbai Medical Miracle: Docs At Wockhardt Hospital Remove Over 7 Centimeters Long & Rare Non-Cancerous Tumour From 63-Year-Old Woman’s Nose

The primary goal of treating a brain aneurysm is to prevent re-bleeding.

Mumbai: 42-Year-Old Saved From Ruptured Brain Aneurysm Through Advanced Endovascular Treatment at Wockhardt Hospital

Shares of Wockhardt hit a multi-year high of Rs 943.20, zooming 65 per cent in past nine trading days.

Pharma shares shine; Dr Reddy’s, FDC, Glenmark, Suven trade at record highs

With two antibiotic products in the last mile ahead of a possible launch in India, Wockhardt Chairman Dr Habil Khorakiwala said, discussions to out-licence them for overseas markets will start only after global approvals come in.

Wockhardt enters last mile to bring two of its promising antibiotics to India

Ion Exchange (India) Ltd, Indo Count Industries Ltd, Emami Ltd and Sharda Cropchem Ltd are among the other gainers in the BSE’s ‘A’ group today, 01 July 2024.

Wockhardt Ltd leads gainers in ‘A’ group

Wockhardt soared 13.64% to Rs 780 after the company’s experimental antibiotic, Zaynich, successfully treated a US cancer patient with a chronic thigh infection caused by extremely resistant bacteria.

Wockhardt soars as Zaynich shows promise against superbugs

Global launch in FY26 after multinational clinical trial ends

Mumbai-based Wockhardt to launch its novel antibiotic Zaynich by FY25-end

The company has invested over $500 million on its research efforts till now.

Wockhardt Launches New Antibiotic With $25-Billion Market Potential

Habil Khorakiwala, Founder & Chairman, Wockhardt gives insights on the newly launched drug Zaynich. It is the first drug to get 64-Breakthrough point from USFDA. He tells that so far Zaynich has treated 30 patients.

#wockhardt #drugnews #ndtvprofit 

For more videos subscribe to our channel: https://www.youtube.com/@NDTVProfitIndia
Visit NDTV Profit for more news: https://www.ndtvprofit.com/
Don't enter the stock market unaware. Read all Research Reports here: https://www.ndtvprofit.com/research-reports

Follow NDTV Profit here
Twitter: https://twitter.com/NDTVProfitIndia , https://twitter.com/NDTVProfit
LinkedIn: https://www.linkedin.com/company/ndtvprofit
Instagram: https://www.instagram.com/ndtvprofit/
Facebook: https://www.facebook.com/NDTVProfit/

Zaynich To Treat Infections Caused By Various Pathogens: Wockhardt Founder & Chairman Gives Insights

Post QIP, Wockhardt’s paid-up equity share capital increased to Rs 76.71 crore, consisting of 15.34 equity shares with a face value of Rs 5 each.

Wockhardt Shares Locked In 5% Upper Circuit After Raising Rs 480 Crore Via QIP

Wockhardt, a leading pharmaceutical company, has successfully raised ₹480 crore through a Qualified Institutional Placement (QIP) at an issue price of Rs.517 per share. Notably, the issue price represents a 5% discount to the QIP floor price of Rs.544 per share, demonstrating investor confidence in the company's potential. Distinguished investors such as Madhusudan Kela, Prashant Jain, and institutional giants like ICICI Prudential and Tata India Opportunities Fund, have participated in this offering, collectively acquiring significant stakes. With this infusion of capital and backing from renowned investors, Wockhardt is poised for accelerated growth and innovation in the pharmaceutical sector
#banknifty  #nifty #niftybank #sensex #niftystrategies #nifty50 #stockmarket #stockmarketanalysis #stocknews
Subscribe To ET Now For Latest Updates On Stocks, Business, Trading | ► https://goo.gl/SEjvK3

Subscribe Now To Our Network Channels :-
Times Now  : http://goo.gl/U9ibPb
The NewsHour Debate : http://goo.gl/LfNgFF

To Stay Updated Download the Times Now App :-
Android Google Play :  https://goo.gl/zJhWjC
Apple App Store :  https://goo.gl/d7QBQZ

Social Media Links :-
Twitter - http://goo.gl/hA0vDt
Facebook - http://goo.gl/5Lr4mC
G+ - http://goo.gl/hYxrmj
Website - www.etnownews.com

Marquee Investors Back Wockhardt's Growth: Raises ₹480Cr in QIP with Support from Industry Titans

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Average profitability - not good, not bad

Profitability

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

The stock has a moderate number of red flags

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Wockhardt Limited manufactures and markets pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines.

Wockhardt Ltd